Tonix Pharmaceuticals Holding Corp.
4:15 PM - 4:30 PM (EDT), Tuesday, June 6, 2023 ・ Session Room 104A
Tonix is a clinical-stage biopharmaceutical company focused on developing therapeutics and vaccines to treat and prevent human disease and alleviate suffering. We have a rich pipeline of products in development that has been curated from internal discovery, as well as licenses, acquisitions and collaborations with academic institutions and contract research organizations. We continue to build capabilities in synthetic biology, precision medicine, protein engineering, medicinal chemistry, molecular biology, pharmacogenomics and clinical-scale manufacturing. Our therapeutics under development include both small molecules and biologics.
Our portfolio consists of central nervous system, rare disease, immunology, and infectious disease product candidates.
The CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions.
Our portfolio consists of central nervous system, rare disease, immunology, and infectious disease product candidates.
The CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions.
Ticker:
TNXP
Exchange:
NASDAQ
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
New Jersey
Company HQ Country:
United States
Year Founded:
2011
Main Therapeutic Focus:
CNS/Neurological
Lead Product in Development:
Our latest stage CNS product candidate is TNX-102 SL*, a proprietary sublingual tablet formulation of cyclobenzaprine (CBP) designed for bedtime administration. TNX-102 SL is in mid-Phase 3 development for the management of fibromyalgia (FM), a pain disorder characterized by chronic widespread pain, non-restorative sleep, fatigue and impaired cognition.
In April 2022, we started a new potentially confirmatory Phase 3 study of TNX-102 SL in FM, RESILIENT. Interim analysis results are expected in the second quarter of 2023 and topline results are expected in the fourth quarter of 2023. Following a positive outcome of the RESILIENT study, Tonix believes we would be positioned to file a New Drug Application (NDA) for TNX- 102 SL for the management of FM.
Development Phase of Primary Product:
Phase III
Number Of Unlicensed Products (For Which You Are Seeking Partners):
8 products from preclinical stage through to Phase III are open for partnering.
Speaker
